Isotechnika ends existing license accord with ILJIN

Isotechnika Pharma (TSX:ISA) has exercised its right to terminate an existing development, distribution and license agreement with ILJIN Life Science of South Korea and is pursuing discussions to potentially change the current relationship with ILJIN in order to better advance its voclosporin program. As a result, Isotechnika has secured full rights to voclosporin for transplant [...]

ILJIN considering control position in Isotechnika

ILJIN Life Science of South Korea, the second largest shareholder of Isotechnika Pharma (TSX:ISA), has verbally informed Isotechnika’s board that ILJIN is planning to “increase their level of control within the company.” The verbal proposal was made by Daniel Park, Executive VP of ILJIN, who has resigned his position as Chief Business Officer of Isotechnika, [...]

Isotechnika in license pact with Vifor Pharma

Isotechnika Pharma (TSX:ISA) has signed a global development and commercialization license agreement with Vifor Pharma, a member of the Swiss Galenica Group, for its lead drug, voclosporin, for the treatment of lupus and all proteinuric nephrology indications, covering the U.S. and other regions outside of Canada, South Africa, Israel, China, Taiwan and Hong Kong. While [...]

Donald Wyatt joins Isotechnika board

Donald Wyatt, the founder of consultancy The Wyatt Group, has been appointed a director of Isotechnika Pharma (TSX:ISA), serving as a representative of 3SBio (NASDAQ:SSRX), a Chinese biotech company. Mr. Wyatt is currently an advisor to 3SBio. He replaces Dr. David Chen, COO of 3SBio, who recently has taken on additional responsibilities that make it [...]

Isotechnika has path forward for pivotal trial

Isotechnika Pharma (TSX:ISA) has taken an important step toward launching final testing of a potential breakthrough drug to prevent rejection of a transplanted kidney. “We now have a clear path forward for a proposed Phase 3 clinical trial protocol of our voclosporin drug,” CEO Dr. Robert Foster says in an exclusive interview with BioTuesdays.com. He [...]

Isotechnika receives positive scientific advice in Europe for voclosporin

Isotechnika Pharma (TSX:ISA) said it has received positive Scientific Advice from the European Medicines Agency for a proposed Phase 3 clinical trial protocol of its drug, voclosporin, after the agency reviewed the study design and endpoints for the proposed clinical study.   This ensures that no major objections regarding the design of the study or the [...]

Isotechnika to be featured on 21st Century Health TV series

Isotechnika Pharma (ISA:TSX) will be featured on 21stCentury Health, an award winning targeted business show that features business leaders across the world and airs on various national cable networks  that are viewed by over 100 million viewers nationwide as well as internationally via DirecTV and Dish Network. The show can also be viewed through video [...]

Isotechnika voclosporin study in AJT

Isotechnika Pharma’s (TSX:ISA) PROMISE study has been published in the American Journal of Transplantation, one of the most respected journals in transplant medicine. The PROMISE study was a Phase 2b, 6-month, randomized, open-label study of three concentration-controlled groups of voclosporin, low, medium, and high, compared with tacrolimus in 334 low-risk kidney transplantation recipients at 36 [...]

Isotechnika names Daniel Park as CBO

Isotechnika Pharma (TSX:ISA) has appointed Daniel Park to the role of chief business officer, reporting directly to CEO Dr. Robert Foster. Mr. Park will oversee all business development operations at Isotechnika, and will specifically help to lead licensing and partnership discussions and negotiations for voclosporin. He will also maintain his position as executive VP of [...]

Isotechnika partner starts uveitis Phase 3 trial

Isotechnika Pharma’s (TSX: ISA) partner Lux Biosciences has begun an additional Phase 3 trial using voclosporin for the treatment of non-infectious uveitis, a leading cause of vision loss and long-term disability. The six-month study will involve 150 patients in North America and Europe with active non-infectious intermediate, posterior, or pan-uveitis. Lux is conducting this additional [...]

Next Page »